Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer

A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most men with CRPC have intact androgen receptor (AR) signaling. As previous work supports negative regulation of MET by A...

Full description

Bibliographic Details
Main Authors: Yuanyuan Qiao, Felix Y. Feng, Yugang Wang, Xuhong Cao, Sumin Han, Kari Wilder-Romans, Nora M. Navone, Christopher Logothetis, Russell S. Taichman, Evan T. Keller, Ganesh S. Palapattu, Ajjai S. Alva, David C. Smith, Scott A. Tomlins, Arul M. Chinnaiyan, Todd M. Morgan
Format: Article
Language:English
Published: Elsevier 2016-01-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558615001542

Internet

http://www.sciencedirect.com/science/article/pii/S1476558615001542

Similar Items